7 Myths and Facts About Type 2 Diabetes

 1-Dessert is still an option. You do need to maintain a healthy weight and consume a balanced diet. However, you can consume sweets in moderation and as part of a balanced diet. 2-In the US, type 2 diabetes is the seventh largest cause of mortality. Nearly 7 out of 10 adults with diabetes over 65 will pass away from heart disease, according to the CDC.  3-A hormone called insulin aids in the body's conversion of sugar to energy. Your cells don't react to type 2 diabetes the…

Comments Off on 7 Myths and Facts About Type 2 Diabetes

A1C Diabetes Test

Everything you need to know about A1c Blood Test For Diabetes What’s on this article ?A1c Test TargetDefinition of A1c Blood TestWhy A1c Test is important for diagnosing diabetesHow Often Do You Need the Hba1c TestA1c LevelsDo You Know Your A1c Target?An A1c test is key if you have diabetes or if your doctor thinks you might have a chance of getting it. It's a common blood test that gives information about your blood sugar.What Is an A1c Test?It’s the main way to find out…

Comments Off on A1C Diabetes Test

Do vitamin D supplements offer kidney-related benefits for individuals with high diabetes risk?

Do vitamin D supplements offer kidney-related benefits for individuals with high diabetes risk? In the general population, low blood vitamin D levels have been associated with higher risks of various diseases, including type 2 diabetes and kidney disease.   Results of a study did not show a benefit of vitamin D supplements on kidney function, About 43% of the study population was taking outside-of-study vitamin D, up to 1000 IU daily, at study entry, though. Among those who were not taking any vitamin D on…

Comments Off on Do vitamin D supplements offer kidney-related benefits for individuals with high diabetes risk?

Timing of eating

Adults who ate their first meal before 8:30 a.m. each day had lower insulin resistance compared with those who started eating after 8:30 a.m., independent of eating interval duration. “The timing of eating is also an important consideration in addition to the duration of eating,” “Our internal biological clocks that control rhythms related to metabolic health play a vital role at the intersection of nutrition and lifestyle that impact metabolic health. Timing of eating was associated with metabolic measures, including insulin resistance, and is a potential area for intervention to combat the increase in metabolic disorders like diabetes.” Analyzed…

Comments Off on Timing of eating

The benefits of cell therapy for type 1 diabetes outweigh risks

The benefits of cell therapy for type 1 diabetes outweigh risks are huge, Read below to discover more. The investigational cell therapy donislecel demonstrated a favorable risk-benefit profile for certain patients with difficult-to-control type 1 diabetes. There is nothing patients [with diabetes] like more than freedom from dealing with the entire insulin issue. This therapy can help some patients and will be incredibly meaningful to those who receive it. Donislecel (Lantidra, CellTrans) — an allogeneic pancreatic islet cellular therapy — has been shown to increase…

Comments Off on The benefits of cell therapy for type 1 diabetes outweigh risks
Read more about the article The benefits of cell therapy for type 1 diabetes outweigh risks
Embryonic stem cells cellular therapy scaled

GLP-1 receptor agonist ‘superior’ for countering weight regain after bariatric surgery

Adults with obesity who regained weight after bariatric surgery saw more effective weight loss with GLP-1 receptor agonist therapy compared with other weight-loss regimens. There are several medications that are approved for weight management (phentermine, topiramate-phentermine, orlistat, bupropion-naltrexone and liraglutide); however, there are limited data to support their use to treat post-bariatric weight regain. Liraglutide is a GLP-1 receptor agonist that is approved for managing type 2 diabetes mellitus and obesity. Studies have shown that postprandial levels of endogenous GLP-1 after bariatric surgery can be…

Comments Off on GLP-1 receptor agonist ‘superior’ for countering weight regain after bariatric surgery
Read more about the article GLP-1 receptor agonist ‘superior’ for countering weight regain after bariatric surgery
Fitness, stretching workout, blond attractive smiling mature woman working out in sports club, keeping fit, doing urdhva mukha shvanasana (upward facing dog pose) in class, full length

Orlistat Therapy for Obesity Linked to Fewer Major Adverse Cardiovascular Events

Orlistat Therapy for Obesity is a revolutionary therapy. People with obesity using orlistat for weight loss may benefit from lower rates of overall major cardiovascular events, new-onset heart failure, renal failure, and mortality. Because diet and lifestyle measures can have variable and limited effects on the initial management of obesity and bariatric surgery remains an invasive and expensive option, pharmacologic weight loss agents provide another weight-loss alternative for individuals with obesity. Orlistat, a lipase inhibitor, is 1 of 4 agents approved by the US Food and…

Comments Off on Orlistat Therapy for Obesity Linked to Fewer Major Adverse Cardiovascular Events

Invokana (Dapagliflozin) Cardiovascular and Renal Benefit

The sodium-glucose co-transporter 2 inhibitor (SGLT2i) dapagliflozin has consistent cardiovascular benefits across baseline kidney-function and albuminuria levels in high-risk patients with type-2 diabetes mellitus (T2DM). Dapagliflozin consistently reduced the relative risk of cardiovascular events irrespective of baseline estimated glomerular filtration rate (eGFR) and albuminuria status in a broad population of patients with T2DM. SGLT2is promote urinary glucose excretion and reduce the risk for cardiovascular death and hospitalizations for heart failure in patients with T2DM. However, The extent of increased glycosuria and, therefore, the glucose-lowering efficacy…

Comments Off on Invokana (Dapagliflozin) Cardiovascular and Renal Benefit

FDA approves once-weekly Semaglutide for weight loss

The FDA approved once-weekly semaglutide for weight loss injection for chronic weight management in adults with obesity or with overweight and at least one weight-related condition Weekly semaglutide 2.4 mg (Wegovy, Novo Nordisk), a GLP-1 receptor agonist, is the first-approved drug for chronic weight management in adults with general obesity or overweight since 2014. Semaglutide for weight loss is indicated for chronic weight management in adults with a BMI of 27 kg/m² or greater who have at least one weight-related comorbidity, such as type 2…

Comments Off on FDA approves once-weekly Semaglutide for weight loss
Read more about the article FDA approves once-weekly Semaglutide for weight loss
Semaglutide for weight loss